EFTUD2 and nonpapillary renal cell carcinoma: Therefore, our study uniquely combines LC-MS/MS proteomics and immunohistochemistry to assess EFTUD2 and PROM1 protein expression in ccRCC, providing novel insights into their prognostic value.